CS-8958 Taiwan Phase 2 study

A randomized, double-blind, placebo-controlled, multi-center phase II study for the evaluation of efficacy and safety of CS-8958 in patients with influenza virus infection

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220797

Enrollment

180

Registered

2009-08-05

Start date

2009-08-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

influenza virus A or B infection

Interventions

investigational material(s) Generic name etc : CS-8958 INN of investigational material : laninamivir Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Clinical diagnosis of influenza -Ear temperature of > or = to 37.8 degrees C

Exclusion criteria

Exclusion criteria: -Infection by bacteria species and/or virus other than influenza virus -Chronic respiratory disease, cardiovascular disease, renal dysfunction, metabolic disorder, immunologic disease and/or other severe complications

Design outcomes

Primary

Measure	Time frame
Time to resolution of fever	—

Secondary

Measure	Time frame
-The safety of CS-8958 in patients with influenza virus infection -The dose response of CS-8958 based on the efficacy	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026